These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 15867221)
1. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221 [TBL] [Abstract][Full Text] [Related]
2. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804 [TBL] [Abstract][Full Text] [Related]
3. [Effect of tissue inhibitors of metalloproteinases (TIMP) on course and prognosis of head and neck squamous cell carcinoma]. Klisho EV; Kondakova IV; Choĭnzonov EL; Shishkin DA; Cheremisina OV; Chuzhevskaia SIu Vopr Onkol; 2009; 55(6):717-21. PubMed ID: 20210014 [TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441 [TBL] [Abstract][Full Text] [Related]
5. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course. Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893 [TBL] [Abstract][Full Text] [Related]
6. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394 [TBL] [Abstract][Full Text] [Related]
7. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas]. Wei QY; Wu YQ; Fan SQ Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069 [TBL] [Abstract][Full Text] [Related]
8. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300 [TBL] [Abstract][Full Text] [Related]
9. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326 [TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma]. Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531 [TBL] [Abstract][Full Text] [Related]
11. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652 [TBL] [Abstract][Full Text] [Related]
12. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma. de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538 [TBL] [Abstract][Full Text] [Related]
13. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. Aljada IS; Ramnath N; Donohue K; Harvey S; Brooks JJ; Wiseman SM; Khoury T; Loewen G; Slocum HK; Anderson TM; Bepler G; Tan D J Clin Oncol; 2004 Aug; 22(16):3218-29. PubMed ID: 15249585 [TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. O-Charoenrat P; Rhys-Evans PH; Eccles SA Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356 [TBL] [Abstract][Full Text] [Related]
16. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Talvensaari-Mattila A; Turpeenniemi-Hujanen T Breast Cancer Res Treat; 2005 Jan; 89(1):29-34. PubMed ID: 15666194 [TBL] [Abstract][Full Text] [Related]
17. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma]. Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Sharma R; Chattopadhyay TK; Mathur M; Ralhan R Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513 [TBL] [Abstract][Full Text] [Related]
20. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T Oncology; 2005; 68(2-3):196-203. PubMed ID: 16006757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]